Özcan Ö et al., 2026-05-05: Animal dose-ranging study of methylene blue (10, 50 or 100 mg/kg IV) in septic rats, framed on the NO/sGC/cGMP pathway that methylene blue inhibits and its use as a catecholamine-sparing adjunct.
Septic shock involves excessive nitric oxide (NO) production and overactivation of the NO/sGC/cGMP pathway, leading to severe vasodilation and microvascular dysfunction. Methylene blue (MB), an inhibitor of this pathway, has been proposed as a catecholamine-sparing adjunct, yet optimal therapeutic dosing remains unclear.
Özcan Ö et al., 2026-05-05: Animal dose-ranging study of methylene blue (10, 50 or 100 mg/kg IV) in septic rats, framed on the NO/sGC/cGMP pathway that methylene blue inhibits and its use as a catecholamine-sparing adjunct. C6 (NO pathway, vasopressor interaction) and C5 (dose range). Funder/conflicts not stated in abstract. Comparator: sham/control and untreated sepsis. Animal doses here are far above human clinical doses and must not be read as human dosing; recorded for the mechanism and dose-response only. Abstract excerpt is two continuous sentences about the pathway, not the results. Study type: animal.
